Germany bans Ranbaxy drug; GlaxoSmithKline best at getting drugs to the poor; Congress to cut funds to those who use pumps instead of Viagra;

@FiercePharma: IMS: Rebates, discounts could take an $80B bite out of U.S. drug spending through 2018. Story | Follow @FiercePharma

@CarlyHFierce: J&J looks for Xarelto boost in real-world cost data. Article | Follow @CarlyHFierce

> Germany has banned over quality issues a Ranbaxy Laboratories drug made at one of the plants already prevented from shipping to the U.S. Story

> GlaxoSmithKline ($GSK) again tops the list of companies that make drugs available to the poor. Story

> Novartis' ($NVS) chronic obstructive pulmonary disease drug Ultibro has been launched in the UK by marketing partner Pfizer ($PFE). Report

Biotech News

@FierceBiotech: Bayer tees up its new #hemophilia drug for an @US_FDA submission. More | Follow @FierceBiotech

@JohnCFierce: Busy biotechs bag $121M in VC cash. Article | Follow @JohnCFierce

@DamianFierce: Considering @GenzymeCorp's party for Cerdelga, how big was the Lemtrada cake? More | Follow @DamianFierce

> Naurex bags an $80M round for PhIII study of an NMDA drug for depression. Article

> Puma tanks on a fresh setback for its breast cancer drug. News

Medical Device News

@FierceMedDev: Edison Nation and Mount Sinai team up for device innovation. More | Follow @FierceMedDev

@EmilyWFierce: Tax-inversion loophole likely to cost the government $2.2B in lost tax revenue next year. Story | Follow @EmilyWFierce

> Illumina and Sequenom lay prenatal diagnostic patent feud to rest. More

> New study supports effectiveness of 3-D breast cancer mammography. News

> Xeltis gets $34M to develop biodegradable heart valves and vessels. Article

Drug Delivery News

> DBV's peanut allergy patch tests well, boosting its market value to almost $1B. Report

> Valerion teams up with Catalent to develop orphan drug delivery tech. News

> Recipharm purchases Flamel facility with delivery partnership. Story

> U.S. Army deploys a novel topical antiseptic to fight ebolavirus. Article

> NIH grants $20M to develop an intravaginal ring to prevent HIV. More

Diagnostics News

> Cepheid wins FDA nod for norovirus test. Report

> Germany's nanoPET partners with Boehringer Ingelheim for imaging Dx deal. News

> Philips gets FDA approval for spectral imaging system. Story

> Roche dives into prenatal Dx space with Ariosa purchase. Item

> U.K. and Wellcome Trust back trial of new, 15-minute Ebola test in West Africa. Article

Pharma Marketing News

> PhIII failure dashes Novartis' hopes of Gilenya label expansion. Report

> Reports: BMS whittles China sales operation by 1,000. More

> J&J looks for Xarelto boost in real-world cost data. Story

> Pfizer believes a dose of confidence will help it sell biosimilars. Link

> IMS: Rebates, discounts could take an $80B bite out of U.S. drug spending through 2018. Article

And Finally... The U.S. Congress may stop an estimated $444 million in Medicare spending for vacuum pumps used to treat erectile dysfunction often used by men who can't afford drugs like Viagra. Story

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.